Cybin Secures $175 Million in Funding to Advance Mental Health Therapeutics
Cybin Inc. has closed a $175 million registered direct offering with top healthcare investors, providing critical capital to advance its Phase 3 clinical programs for novel mental health treatments addressing major depressive disorder and generalized anxiety disorder.
